Literature DB >> 8630922

In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate.

T Janssen1, F Darro, M Petein, G Raviv, J L Pasteels, R Kiss, C C Schulman.   

Abstract

BACKGROUND: Proliferation of normal and tumoral prostate tissue is regulated by androgens and various growth factors. We characterized the in vitro proliferative influence of prolactin (PRL) in androgen-sensitive and androgen-insensitive human prostate cancers.
METHODS: The biologic models employed included the androgen-sensitive LNCaP and the androgen-insensitive DU145 and PC3 cell lines. PRL-induced influences (0.1-10 mIU/ml of medium) on proliferation were assessed using the colorimetric methylthiotetrazole assay. Androgen sensitivity in the three cell lines was determined by assessing the proliferative influence of dihydrotestosterone (DHT) (0.1-10 nM). PRL-induced modifications in PC3 cell kinetics were assessed using Feulgen-stained nuclear image cytometry.
RESULTS: Although DHT markedly stimulated LNCaP proliferation, it had no proliferative effect on the DU145 and PC3 cell lines. By contrast, PRL significantly modulated the proliferation of the DU145 and PC3 lines, but exerted weak, if any, effect on the proliferation of the LNCaP cell line. PRL increased the percentage of PC3 proliferating cells (i.e., cells in the S/G2 phases of the cell cycle) at low doses (0.1 mIU/mL) and decreased this percentage at high doses (10 mIU/ml).
CONCLUSIONS: Proliferation of androgen-insensitive human prostate cell lines can be significantly modulated by prolactin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630922     DOI: 10.1002/(SICI)1097-0142(19960101)77:1<144::AID-CNCR24>3.0.CO;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Antiproliferative activity of 2,3-disubstituted indoles toward apoptosis-resistant cancers cells.

Authors:  Igor V Magedov; Florence Lefranc; Liliya V Frolova; Laetitia Moreno Y Banuls; Amanda S Peretti; Snezna Rogelj; Véronique Mathieu; Robert Kiss; Alexander Kornienko
Journal:  Bioorg Med Chem Lett       Date:  2013-04-08       Impact factor: 2.823

2.  Prolactin stimulates prostate cell proliferation by increasing endoplasmic reticulum content due to SERCA 2b over-expression.

Authors:  Alexandre Crépin; Gabriel Bidaux; Fabien Vanden-Abeele; Etienne Dewailly; Vincent Goffin; Natalia Prevarskaya; Christian Slomianny
Journal:  Biochem J       Date:  2007-01-01       Impact factor: 3.857

Review 3.  Prolactin regulation of the prostate gland: a female player in a male game.

Authors:  Vincent Goffin; David T Hoang; Roman L Bogorad; Marja T Nevalainen
Journal:  Nat Rev Urol       Date:  2011-10-04       Impact factor: 14.432

4.  Does prolactin induce apoptosis? Evidences in a prostate cancer in vitro model.

Authors:  D Giuffrida; A Perdichizzi; M C Giuffrida; S La Vignera; R D'Agata; E Vicari; A E Calogero
Journal:  J Endocrinol Invest       Date:  2009-12-04       Impact factor: 4.256

5.  Generation and analysis of an androgen-responsive myoblast cell line indicates that androgens regulate myotube protein accretion.

Authors:  Y Chen; N K L Lee; J D Zajac; H E MacLean
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

6.  UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.

Authors:  Tatjana Mijatovic; Tina Mahieu; Céline Bruyère; Nancy De Nève; Janique Dewelle; Gentiane Simon; Mischaël J M Dehoux; Ellen van der Aar; Benjamin Haibe-Kains; Gianluca Bontempi; Christine Decaestecker; Eric Van Quaquebeke; Francis Darro; Robert Kiss
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

Review 7.  What can we learn from rodents about prolactin in humans?

Authors:  Nira Ben-Jonathan; Christopher R LaPensee; Elizabeth W LaPensee
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

8.  Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway.

Authors:  Leticia Oliveira-Ferrer; Jasmin Wellbrock; Udo Bartsch; Eva Maria Murga Penas; Jessica Hauschild; Marianne Klokow; Carsten Bokemeyer; Walter Fiedler; Gunter Schuch
Journal:  Mol Cancer       Date:  2013-11-20       Impact factor: 27.401

9.  MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer.

Authors:  Xiaoli Li; Yasai Ji; Gaoyang Han; Xiaoran Li; Zhirui Fan; Yaqing Li; Yali Zhong; Jing Cao; Jing Zhao; Mingzhi Zhang; Jianguo Wen; Mariusz Adam Goscinski; Jahn M Nesland; Zhenhe Suo
Journal:  BMC Cancer       Date:  2016-11-16       Impact factor: 4.430

10.  Qianlie Xiaozheng Decoction Induces Autophagy in Human Prostate Cancer Cells via Inhibition of the Akt/mTOR Pathway.

Authors:  Yuehua Xu; Xueting Cai; Bin Zong; Rui Feng; Yali Ji; Gang Chen; Zhongxing Li
Journal:  Front Pharmacol       Date:  2018-04-04       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.